<p>Disclosed is a novel mastitis vaccine. More specifically disclosed is a novel mastitis vaccine, which can efficiently induce humoral or cellular transmucosal immune responses mainly including the production of IgA antibodies. A liposome containing a membrane-fusogenic lipid (methylglutaryl-modified polyglycidol) is used as a vaccine carrier. The mastitis vaccine comprises a vaccine carrier comprising a liposome containing methylglutaryl-modified polyglycidol and an immunogen contained in the vaccine carrier.</p>
